Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cytokinetics is a late-stage biopharmaceutical company focused on muscle biology therapeutics, with lead candidate aficamten targeting hypertrophic cardiomyopathy (HCM) and omecamtiv mecarbil for heart failure. The company has no commercial revenue yet but is approaching potential FDA approval decisions in 2026-2027 for aficamten, which could address a $3-5 billion HCM market. Stock performance is driven entirely by clinical trial readouts, regulatory milestones, and partnership announcements rather than operational fundamentals.
Cytokinetics operates a binary risk/reward model typical of clinical-stage biotechs. The company advances proprietary muscle activator and inhibitor compounds through Phase 2/3 trials, funded by equity raises and partnership deals. Monetization occurs through: (1) upfront/milestone payments from pharma partners who license geographic or indication rights, (2) royalties on partner-commercialized products, and (3) direct commercialization of approved drugs in retained territories. Aficamten (cardiac myosin inhibitor) represents the primary near-term value driver with SEQUOIA-HCM Phase 3 data supporting potential 2026-2027 FDA approval. The company has limited pricing power until approval but benefits from orphan/rare disease designations that provide market exclusivity and premium pricing potential in the $100K-200K annual treatment cost range for HCM therapies.
Aficamten Phase 3 trial data readouts and FDA submission timing for obstructive HCM indication
FDA Advisory Committee meetings and approval decisions (PDUFA dates) for lead candidates
Partnership announcements, licensing deals, or milestone payment triggers with pharma partners
Clinical trial enrollment rates and timeline updates for pipeline programs (omecamtiv mecarbil, aficamten label expansions)
Equity financing announcements and cash runway updates given $400M annual burn rate
Binary regulatory risk - FDA rejection or clinical trial failure of aficamten would eliminate 70-80% of current valuation given pipeline concentration
Reimbursement pressure from payers challenging specialty drug pricing, particularly for cardiovascular indications without mortality benefit data
Manufacturing scale-up risk transitioning from clinical to commercial production without established infrastructure
Patent cliff exposure with key composition-of-matter patents expiring 2030s, limiting commercial exclusivity window
Bristol Myers Squibb's mavacamten (Camzyos) already approved for obstructive HCM with 2+ year head start and established market presence
Multiple cardiac myosin inhibitors in development (BMS next-gen compounds, other competitors) targeting same patient population
Established heart failure therapies (SGLT2 inhibitors, ARNIs) expanding indications into Cytokinetics' target markets
Risk of superior efficacy/safety profiles from competitor programs rendering pipeline assets non-competitive
Cash burn of $400M annually provides approximately 2.5-3 year runway, requiring additional capital raises that dilute existing shareholders
Negative operating cash flow and no revenue generation creates dependence on capital markets access during potential downturns
Highly negative ROA (-52.3%) and extreme negative margins reflect pre-revenue status with no near-term path to profitability without approval
Equity financing risk - inability to raise capital at current valuations could force unfavorable partnership terms or asset sales
low - Pre-revenue biotech valuations are largely decoupled from GDP and economic cycles, driven instead by binary clinical/regulatory events. However, severe recessions can impact: (1) ability to raise capital at attractive valuations, (2) pharma partners' willingness to execute licensing deals, and (3) healthcare system capacity to enroll clinical trials. The company's $8.2B market cap reflects discounted probability-weighted future cash flows from potential approvals rather than current economic conditions.
High sensitivity to interest rates through valuation multiples rather than operations. As a pre-revenue growth asset, CYTK is valued on discounted cash flows from products potentially launching 2027-2030+. Rising rates increase discount rates applied to distant cash flows, compressing valuations significantly. The 10-year Treasury yield directly impacts biotech sector multiples - the 2022 rate spike caused sector-wide 50-70% drawdowns. Additionally, higher rates increase opportunity cost of holding cash-burning assets and can tighten venture/growth capital availability for follow-on financings.
Minimal direct credit exposure as the company has no debt (negative debt/equity ratio indicates more cash than debt) and does not extend customer credit. However, credit market conditions indirectly affect: (1) ability to access capital markets for equity raises needed to fund operations, (2) pharma partners' financial flexibility to execute licensing deals and pay milestones, and (3) broader risk appetite for speculative growth assets. Widening high-yield spreads typically correlate with biotech sector underperformance as investors rotate to safety.
growth - Attracts speculative growth investors and biotech specialists willing to accept binary risk/reward profiles. The 77% six-month return and 44% one-year return reflect momentum-driven trading around clinical catalysts. Institutional ownership likely dominated by healthcare-focused hedge funds and venture capital rather than value or income investors. High volatility and event-driven nature appeals to options traders around FDA decision dates and trial readouts. Not suitable for risk-averse or income-focused investors given negative cash flows and no dividend potential.
high - Clinical-stage biotechs exhibit extreme volatility with single-day moves of 30-50%+ common around trial data releases and regulatory decisions. The stock's 77% six-month gain demonstrates momentum characteristics. Implied volatility typically spikes 2-3x baseline levels approaching binary events. Beta likely exceeds 1.5-2.0x relative to broader market, with sector-specific risk dominating idiosyncratic company performance. Options markets price significant event risk around PDUFA dates and trial readouts.
